Intuitive Surgical ISRG
Intuitive Surgical is a medical technology company that designs, manufactures, and sells robotic surgical systems (such as da Vinci), along with instruments and accessories, and generates recurring revenue from the use of its platforms. Intuitive Surgical maintains solid financial health (net cash, operating margin 33.6%) and robust growth (revenue +18.5%), but its demanding valuation (P/E 46.5) and negative momentum (-15.5%) limit near-term appeal.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Intuitive Surgical is a medical technology company that designs, manufactures, and sells robotic surgical systems (such as da Vinci), along with instruments and accessories, and generates recurring revenue from the use of its platforms. Intuitive Surgical maintains solid financial health (net cash, operating margin 33.6%) and robust growth (revenue +18.5%), but its demanding valuation (P/E 46.5) and negative momentum (-15.5%) limit near-term appeal.
Score by category
| Category | Score |
|---|---|
| Financial health | 8.8 |
| Quality / Moat | 7.7 |
| Valuation | 2.7 |
| Growth | 8.1 |
| Dividend | 1.5 |
| Momentum | 2.4 |
| Risk & Context | 4.1 |
OVERALL SCORE: 5.5/10
Context and risks
No material exposure to interest rates, nor to commodities or geopolitics. The healthcare sector is defensive and unaffected by the current macro context.
News considered in the analysis
- Can This Number Push ISRG Stock Higher? — Artículo especulativo sin información nueva sobre la empresa.
- Buy 3 AI-Powered Medical Stocks to Strengthen Your Portfolio in Q4 — Listículo promocional sin datos concretos sobre ISRG.
- Intuitive Surgical Stock Has Plunged 29% This Year. Is the Market Overreacting? — La caída del 29% ya está en el precio; el artículo no aporta información nueva.
- Intuitive Surgical vs. Stryker: Which MedTech Stock Is the Better Buy Now? — Comparativa genérica sin impacto en valoración.
- 2 Beaten-Down Stocks to Buy Before They Bounce Back — Opinión de compra sin información nueva.
Verdict: Hold: fundamentals are strong, but high valuation and weak momentum suggest waiting for a better entry point.
Main risk: The demanding valuation (P/E 46.5) leaves little room for error if revenue growth decelerates or competition in surgical robotics intensifies.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →